Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocon Limited ( (IN:BIOCON) ) has shared an update.
Biocon Biologics, a subsidiary of Biocon Limited, has announced a settlement and license agreement with Amgen Inc., allowing the company to commercialize its denosumab biosimilars, Bosaya and Aukelso, in the U.S. market starting October 1, 2025. This development follows the U.S. FDA’s approval and provisional interchangeability designation for these products, which are biosimilars to Amgen’s Prolia and Xgeva. The agreement resolves pending patent litigation and marks Biocon Biologics’ entry into the bone health space, enhancing its oncology portfolio and reaffirming its position as a global leader in biosimilars.
More about Biocon Limited
Biocon Limited is a global biopharmaceutical company based in India, primarily focused on biosimilars, generic formulations, and novel biologics. The company operates in the healthcare sector, with a market focus on providing affordable and accessible medicines across various therapeutic areas, including oncology and bone health.
Average Trading Volume: 127,035
Technical Sentiment Signal: Buy
Current Market Cap: 453.9B INR
For a thorough assessment of BIOCON stock, go to TipRanks’ Stock Analysis page.